SCHEMBL10126992

SCHEMBL10126992

CC(=O)c1cc([N+](=O)[O-])ccc1N1CCN(C)CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 16/20 0.71
LMNA P02545 3/20 0.71
GAA P10253 2/20 0.71
KMT2A Q03164 3/20 0.70
POLB P06746 1/20 0.70
MEN1 O00255 2/20 0.68
CYP1A2 P05177 1/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2D6 P10635 1/20 0.68
CYP2C9 P11712 1/20 0.68
CYP2C19 P33261 1/20 0.68
KDM4E B2RXH2 1/20 0.65
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
HTT P42858 1/20 0.57
WDR5 P61964 2/20 0.57
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972566 0.89 ALDH1A1 (0.75) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL10689021 0.89 ALDH1A1 (0.74) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL12005978 0.88 ALDH1A1 (0.66) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL16305341 0.85 ALDH1A1 (0.67) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL4159162 0.85 ALDH1A1 (0.76) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL10126964 0.85 ALDH1A1 (0.73) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL13312222 0.85 SMN1; SMN2 (0.74) ALDH1A1LMNAKMT2APOLBMEN1
SCHEMBL15961263 0.84 ALDH1A1 (0.66) ALDH1A1LMNAGAAKMT2APOLB
Acetic Acid SCHEMBL27840869 0.84 ALDH1A1 (0.95) ALDH1A1LMNAGAAKMT2APOLB
SCHEMBL27954071 0.83 ALDH1A1 (1.00) ALDH1A1LMNAGAAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023011610-A1 BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 南京红云生物科技有限公司 2023-02-09 WO disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885LMNA 2845/4885GAA 3821/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885LMNA 2845/4885GAA 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.